Chemistry: molecular biology and microbiology – Animal cell – per se ; composition thereof; process of... – Method of regulating cell metabolism or physiology
Reexamination Certificate
2008-04-15
2008-04-15
Saunders, David A. (Department: 1644)
Chemistry: molecular biology and microbiology
Animal cell, per se ; composition thereof; process of...
Method of regulating cell metabolism or physiology
C435S355000, C435S372000, C435S377000, C424S192100, C424S193100
Reexamination Certificate
active
09954349
ABSTRACT:
Molecular adjuvants are disclosed comprising an antigen presenting cell-targeting ligand linked to an immunogen. In particular, these molecular adjuvants are employed in compositions designed to deliver the specific immunogen to antigen presenting cells and simultaneously deliver signals to those cells that produce the desired immune response. Methods are also disclosed for delivery of these molecular adjuvants to patients, resulting in the transduction of activating signals to the targeted antigen presenting cell, thereby enhancing the immune response to the co-delivered immunogen.
REFERENCES:
patent: 4950480 (1990-08-01), Barber et al.
patent: 5032401 (1991-07-01), Jamas et al.
patent: 5073627 (1991-12-01), Curtis et al.
patent: 5262303 (1993-11-01), Sipe et al.
patent: 5696230 (1997-12-01), Sanderson et al.
patent: 5827666 (1998-10-01), Finn et al.
patent: 5942599 (1999-08-01), Sanderson et al.
patent: 5976546 (1999-11-01), Laus et al.
patent: 5989552 (1999-11-01), McKenzie et al.
patent: 6086875 (2000-07-01), Blumberg et al.
patent: 6248332 (2001-06-01), Romet-Lemonne et al.
patent: 6465614 (2002-10-01), Sanderson et al.
patent: 6821517 (2004-11-01), Sanderson et al.
patent: 7063847 (2006-06-01), Sanderson et al.
patent: 2002/0091234 (2002-07-01), Sanderson et al.
patent: 2005/0025784 (2005-02-01), Sanderson et al.
patent: 2005/0089524 (2005-04-01), Sanderson et al.
patent: 2007/0031445 (2007-02-01), Sanderson et al.
patent: 0 145 174 (1985-06-01), None
patent: 2 177 514 (1983-10-01), None
patent: WO 89/12458 (1989-12-01), None
patent: WO 92/05793 (1992-04-01), None
patent: WO 92/11031 (1992-07-01), None
patent: WO 93/10814 (1993-06-01), None
patent: WO 95/25957 (1995-09-01), None
patent: 96/06629 (1996-03-01), None
patent: WO 96/22377 (1996-07-01), None
patent: 9714426 (1997-04-01), None
Grosjean, I et al. Eur. J. Immunol. [1994] 24(12):2982-2986.
Barclay et al., “GM-CSFR, Granulocyte-Macrophage Colongy-Stimulating Factor Receptor.” The Leucocyte Antigen Facts Book, 1997, Second Edition, Academic Press, London.
Guyre et al., “Monoclonal Antibodies that Bind to Distinct Epitopes on FcγRI are Able to Trigger Receptor Function.” The Journal of Immunoogy, 1989, pp. 1650-1655, vol. 143, No. 5.
Kennedy et al., “Protein-Protein Coupling Reactions and the Applications of Protein Conjugates.” Clinica Chimica Acta, 1976, pp. 1-31, vol. 70.
Buchner et al., Anti-Human kappa opioid receptor antibodies characterization of site-directed neutralizing antibodies specific for a peptide kR(33-52) derived from the predicted amino-terminal region of the human kappa receptor,J. Immunol., 1996, pp. 1670-1680, vol. 158.
Ember et al., Biological activity of synthetic analogues of C5a anaphylatoxin,J. Immunol., 1992, pp. 3165-3173, vol. 148.
Goodman et al.,Potentiation of the Primary Humoral Immune Response In Vitro by C5a Anaphylatoxin,J. Immunol., Jul. 1982, vol. 129, No. 1.
Hobbs et al., Induction of human B cell differentiation by Fc region activators. I. Identification of an active tetrapeptide,Clin. Immunol. Immunopathol., 1989, p. 251, vol. 50.
Morgan et al., Anti-C5a receptor antibodies. I. Charaterization of neutralizing antibodies specific for the human C5a receptor,J. Immunol., 1993, p. 377, vol. 151.
Morgan, Regulation of human B lymphocyte activation by opioid peptide hormones. Inhibition of lgG production by opioid receptor class (μ-, κ-, and σ-) selective agonists,J. Neuroimmunol., 1996, p. 21, vol. 65.
Rammensee et al., Peptides Naturally Presented by MHC Class I Molecules,Ann. Rev. Imm., 1993, pp. 213-244, vol. 11.
Sanderson et al., Decapeptide agonists of human C5a: the relationship between conformation and spasmogenic and platelet aggregatory responses,J. Med Chem., 1994, pp. 3171-3180, vol. 38.
Tong et al., Monoclonal antibody against α(1→3) dextran transfers suppression of the immune response to acetylcholine receptor,Eur. J. Immunol., 1990, pp. 1635-1639, vol. 20.
Tempero, R.M., et al., “Molecular Adjuvant Effects of a Conformationally Biased Agonist of Human C5a Anaphylatoxin”, J. Immunology, vol. 158:1377-1382 (1997).
Baier, G., et al., “Immunogenic Targeting of Recombinant Peptide Vaccines to Human Antigen-Presenting Cells by Chimeric Anti-HLA-DR and Anti-Surface Immunoglobulin D Antibody Fab Fragments In Vitro”, J. Virology, vol. 69: 2357-2365 (1995).
Campbell, Monoclonal Antibody Technology, Elsevier Sciences, p. 1-32, (1984).
Kuby, Immunology, 2nd Ed., W.H. Freeman and Co.,, pp. 89-91, 123, 297-306, (1994).
Sanderson, S.D. et al. “Decapeptide Agonists of Human C5a: The Relationship between Conformation and Neutrophil Response”; J. Med. Chem., 38(18): 3669-3675 (1995).
Hollingsworth Michael A.
Sanderson Sam D.
Tempero Richard A.
Board of Regents of The University of Nebraska
Dann Dorfman Herrell & Skillman P.C.
Netter Robert C.
Saunders David A.
VanderVegt F. Pierre
LandOfFree
Compositions and methods for enhancing immune responses... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for enhancing immune responses..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for enhancing immune responses... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3935825